Updates are available Correction dated 2024-06-24
Click to view Correction: https://doi.org/10.1038/s41591-024-03129-w
-
Authors
Mukohara, Toru
Park, Yeon Hee https://orcid.org/0000-0003-4156-9212
Sommerhalder, David https://orcid.org/0000-0002-7033-9064
Yonemori, Kan https://orcid.org/0000-0002-7624-7611
Hamilton, Erika https://orcid.org/0000-0002-1911-0336
Kim, Sung-Bae
Kim, Jee Hyun
Iwata, Hiroji
Yamashita, Toshinari https://orcid.org/0000-0002-6479-1660
Layman, Rachel M. https://orcid.org/0000-0002-8663-0331
Mita, Monica
Clay, Timothy
Chae, Yee Soo
Oakman, Catherine
Yan, Fengting
Kim, Gun Min
Im, Seock-Ah
Lindeman, Geoffrey J. https://orcid.org/0000-0001-9386-2416
Rugo, Hope S. https://orcid.org/0000-0001-6710-4814
Liyanage, Marlon https://orcid.org/0000-0003-3801-6174
Saul, Michelle
Le Corre, Christophe
Skoura, Athanasia
Liu, Li
Li, Meng https://orcid.org/0009-0002-5406-8345
LoRusso, Patricia M. https://orcid.org/0000-0001-7144-036X
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 23 April 2024
Accepted: 10 May 2024
First Online: 1 June 2024
Change Date: 24 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-03129-w
Competing interests
: T.M. received honoraria from AstraZeneca, Chugai Pharma, Eisai, Kyowa Kirin, Lilly Japan, Novartis, Pfizer and Taiho Pharmaceutical; had a consulting or advisory role at Eisai and Micin; and received research funding from AstraZeneca, Chugai Pharma, Daiichi Sankyo/AstraZeneca, Eisai, Gilead Sciences, MSD, Novartis, Ono Pharmaceutical, Pfizer, Sanofi and Sysmex. Y.H.P. received honoraria from AstraZeneca, Daiichi Sankyo, Eisai, Lilly, MSD, Novartis, Pfizer and Roche; had a consulting or advisory role at AstraZeneca, Boryung, Daiichi Sankyo, Eisai, Gilead Sciences, Lilly, Menarini, MSD, Novartis, Pfizer and Roche; received research funding from AstraZeneca, Pfizer, Gencurix, Genome Insight, NGeneBio and Roche; and received travel and accommodation expenses from Gilead. D.S. was employed at Texas Oncology; had stock and other ownership interests in Texas Oncology and NEXT Oncology; received honoraria from Syneos Health; had a consulting or advisory role at Guidepoint and Revolution Medicines; and received research funding from Abbvie, ADC Therapeutics, Ascentage Pharma, Biomea Fusion, BioNTech SE, BJ Bioscience, Boehringer Ingelheim, Fate Therapeutics, Gilead Sciences, Immuneering, Kura Oncology, MediLink, Mirati Therapeutics, Monopteros Therapeutics, Navire, NGM Biopharmaceuticals, Nimbus Therapeutics, OncoResponse Inc., Pfizer, Revolution Medicines, Symphoge, Tachyon Therapeutics, Teon Therapeutics and ZielBio. K.Y. received honoraria from AstraZeneca, Chugai Pharma, Daiichi Sankyo/AstraZeneca, Eisai, Fujifilm, Lilly Japan, MSD Oncology, Novartis, Ono Pharmaceutical, Pfizer, Taiho Pharmaceutical and Takeda; had a consulting or advisory role at Chugai Pharma, Eisai, Henlius, Novartis, OncXerna Therapeutics and Ono Pharmaceutical; and received research funding from AstraZeneca/MedImmune, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo/AstraZeneca, Eisai, Genmab, Haihe Pharmaceutical, Kyowa Kirin, Lilly, MSD, Nihonkayaku, Novartis, Ono Pharmaceutical, Pfizer, Sanofi, Seagen, Taiho Pharmaceutical and Takeda. E.H. had a consulting or advisory role at AstraZeneca, Daiichi Sankyo, Ellipses Pharma, Genentech/Roche, Greenwich LifeSciences, ITeos Therapeutics, Janssen, Lilly, Loxo, Mersana, Novartis, Olema Pharmaceuticals, Orum Therapeutics, Pfizer, Relay Therapeutics, Seagen, Stemline Therapeutics, Theratechnologies, Tubulis GmbH and Verascity Science; and received research funding from Abbvie, Accutar Biotech, Acerta Pharma, ADC Therapeutics, Akeso Biopharma, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond Therapeutics, Bliss Biopharmaceutical, Boehringer Ingelheim, Cascadian Therapeutics, Clovis Oncology, Compugen, Context Therapeutics, Cullinan Oncology, Curis, CytomX Therapeutics, Daiichi Sankyo, Dana Farber Cancer Hospital, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Ellipses Pharma, Elucida Oncology, EMD Serono, Fujifilm, G1 Therapeutics, Genentech/Roche, H3 Biomedicine, Harpoon, Hutchison MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, InventisBio, Jacobio, K-Group Beta, Karyopharm Therapeutics, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo, Lycera, MabSpace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Novartis, Nucana, Olema Pharmaceuticals, OncoMed, Onconova Therapeutics, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr, Plexxikon, Prelude Therapeutics, ProfoundBio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicines, Rgenix, Seagen, Sermonix Pharmaceuticals, Shattuck Labs, Stem CentRx, Sutro Biopharma, Syndax, Syros Pharmaceuticals, Taiho Pharmaceutical, TapImmune Inc, Tesaro, Tolmar, Torque, Treadwell Therapeutics, Verastem, Zenith Epigenetics and Zymeworks. S.-B.K. holds stock and other ownership Interests of Genopeaks; received honoraria from DAEHWA Pharmaceutical, Kalbe Farma and LegoChem Biosciences; had a consulting or advisory role at AstraZeneca, BeiGene, DAEHWA Pharmaceutical, Daiichi Sankyo/AstraZeneca, Ensol Biosciences, ISU Abxis, Lilly and OBI Pharma; and received research funding from Genzyme. J.H.K. received honoraria from Roche Korea, AstraZeneca Korea, Lilly Korea, Roche diagnostics and Roche; had a consulting or advisory role at Bixink, Eisai Korea, Roche, MSD Korea, Everest Medicine and Yuhan; and received research funding from Ono Pharma Korea, Roche and Eisai. H.I. received honoraria from AstraZeneca, Chugai, Daiichi Sankyo, Kyowa Kirin, Lilly, MSD, Pfizer and Taiho; had a consulting or advisory role at AstraZeneca, Chugai, Daichi Sankyo, Gilead, Lilly, MSD and Pfizer; and received research funding from AstraZeneca, Chugai and Daiichi Sankyo. T.Y. received honoraria from AstraZeneca, Chugai Pharma, Daiichi Sankyo, Eisai, Kyowa Kirin, Lilly, Pfizer and Taiho Pharmaceutical; and received research funding from AstraZeneca, Chugai Pharma, Daiichi Sankyo, Kyowa Kirin, Lilly, MSD, Nihonkayaku, Pfizer, Seagen and Taiho Pharmaceutical. R.M.L. received honoraria from Pfizer; had a consulting or advisory role at Eli Lilly, Novartis, Pfizer, Celcuity, Gilead Sciences and Biotheryx; and received research funding to institution from Eli Lilly, Novartis, Pfizer, Puma, Zentalis, Celcuity, Arvinas and Accutar Biotechnology. T.D.C. received honoraria from Lilly, Specialised Therapeutics, Roche, MSD and The Limbic; had a consulting or advisory role for AstraZeneca/MedImmune, Merck KGaA, Takeda, Merck/Pfizer, Ipsen, AstraZeneca, Daiichi Sankyo, Janssen and Roche; was a member of Speakers’ Bureau of AstraZeneca/MedImmune; and received research funding from Abbvie, Amgen, Bayer, BeiGene, Clovis Oncology, Daiichi Sankyo/AstraZeneca, Exelixis, Immutep, Janssen Oncology, MSD Oncology, Pfizer, BridgeBio Pharma and Bristol Myers Squibb GmbH & Co. K.G. held stock and other ownership Interests of ClinicIQ; and received travel and accommodation expenses from AstraZeneca, Daiichi Sankyo/UCB Japan and Boehringer Ingelheim. F.Y. received honoraria from Daiichi Sankyo, Merck, AstraZeneca, Grail, Gilead, Stemline, Eli Lilly, SeaGen and GE; and received research funding from Pfizer, Gilead, Merck, Agendia and Genentech. S.-A.I. received honoraria from MSD Korea; had a consulting or advisory role at AstraZeneca, Bertis, Daiichi Sankyo, Eisai, Gilead, Lilly, MSD, Novartis, Pfizer and Roche; and received research funding from AstraZeneca, Daiichi Sankyo, Boryung Pharm, Daewoong Pharm, Eisai, Roche and Pfizer. G.J.L. received honoraria from Pfizer; had a consulting or advisory role at Pfizer and AbbVie; and received research funding from AbbVie, Amgen, Genentech and Pfizer (all study support to Institution for investigator-initiated studies) and Cooperative Research Centre for Cancer Therapeutic, Australia (laboratory funding). H.S.R. had a consulting or advisory role at Daiichi Sankyo, Eisai, Mylan, Napo Pharmaceuticals and Puma Biotechnology; and received research funding from Astellas Pharma, AstraZeneca, Daiichi Sankyo, Genentech/Roche, Gilead Sciences, GSK, Lilly, Merck, Novartis, OBI Pharma, Pfizer, Stemline Therapeutics, Taiho Oncology and Veru. P.M.L.R. received honoraria from Five Prime Therapeutics; had a consulting or advisory role at Abbvie, ABL Bio, Actuate Therapeutics, Agenus, Amgen, AstraZeneca, Atreca, BAKX Therapeutics, Boehringer Ingelheim, Compass Therapeutics, Cullinan Oncology, DAAN Biotherapeutics, EMD Serono, GSK, I-Mab, ImCheck therapeutics, IQvia, Kineta, Kyowa Kirin International, Mekanistic Therapeutics, Mersana, Molecular Templates, Neurotrials Research, Pfizer, QED Therapeutics, Qualigen Therapeutics, Quanta Therapeutics, Relay Therapeutics, Roche/Genentech, Roivant, Scenic Biotech, Schrodinger, Seagen, Sotio, ST Cube, Stemline Therapeutics, Takeda and Zentalis; received research funding from Genentech; and received travel and accommodation expenses from Genentech. M.L. has a patent royalty from the Johns Hopkins University; is employed at Pfizer; and owns stock and other ownership interests of Pfizer. M.L., C.L.C., A.S., L.L. and M.S. are employed at Pfizer; and own stock and other ownership interests of Pfizer. The other authors have no competing interests.
